SB Avandia, Takeda/Lilly Actos Antidiabetics Set For Advisory Cmte. Review
SmithKline Beecham's Avandia and Takeda/Lilly's Actos have been scheduled for review by an FDA advisory committee one month after the agency plans to discuss the safety of the first "glitazone" insulin sensitizer Rezulin.
You may also be interested in...
The risk of lactic acidosis associated with Bristol-Myers Squibb's Glucophage should not be compared to liver toxicities associated with Rezulin because the Glucophage side effects can be more easily managed through education, FDA consultant Saul Genuth, MD, Case Western Reserve University, told FDA's Endocrinologic & Metabolic Drugs Advisory Committee.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011